Evidence map›Paper›PMID 41184296›Full record

ArticleNPJ vaccines2025

Inverted H1 hemagglutinin nanoparticle vaccines protect mice against challenges with human H1N1 and bovine H5N1 influenza viruses.

Asim Biswas, Kathryn Loeffler, Donguk Kim, Amie J Eisfeld, Augustine Duffy, Hunter Hammond, Anjali Sangappa, Hassanein H Abozeid, Gabriele Neumann, Alberto Moreno and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Asim Biswas *Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53711, USA.
Kathryn Loeffler *School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Donguk Kim *School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Amie J EisfeldInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53711, USA.
Augustine DuffySchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Hunter HammondSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Anjali SangappaSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Hassanein H AbozeidInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53711, USA.
Gabriele NeumannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53711, USA.
Alberto MorenoEmory Vaccine Center, Emory University, Atlanta, GA, 30329, USA. camoren@emory.edu.
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53711, USA. yoshihiro.kawaoka@wisc.edu.
Ravi S KaneSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA. ravi.kane@chbe.gatech.edu.

Funding

Engineering Protein Antigens and their Presentation from Multivalent ScaffoldsR01AI168408 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI Ravi S. Kane, Alberto Moreno · 2023 to 2026
$3.3M
T32 Research Training Program in ImmunoEngineeringT32EB021962 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI JULIA E BABENSEE · 2017 to 2026
$1.9M
National Science Foundation DGE-2039655NIAID NIH HHS R01 AI168408NIBIB NIH HHS T32 EB021962NIH HHS R01 AI168408-01A1
6 · The paper itself

Abstract

Influenza is a global health concern, causing over 300,000 deaths worldwide annually. Current vaccines and natural infection mainly elicit antibodies against the variable head domain of the hemagglutinin (HA) glycoprotein. While these antibodies are highly neutralizing, the head domain constantly mutates due to selective pressure, causing the immune response to be strain-specific. Targeting the conserved HA stalk domain, however, has been shown to be a promising approach for a broadly protective vaccine. We previously demonstrated that presenting HA in an inverted orientation on virus-like particles (VLPs) significantly enhanced the induction of stalk-directed, cross-reactive antibodies compared to HA presented in a regular orientation. Here, we evaluated the protective efficacy of the inverted HA vaccine (VLP-HA

Identifiers

PMID41184296
PMCPMC12583477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.